Danaher Corporation (DHR)
$
212.2
+3.19 (1.50%)
Key metrics
Financial statements
Free cash flow per share
6.7858
Market cap
151.9 Billion
Price to sales ratio
6.3277
Debt to equity
0.3545
Current ratio
1.6194
Income quality
1.8075
Average inventory
2.6 Billion
ROE
0.0669
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Danaher Corporation designs, manufactures, and markets a wide array of professional, medical, industrial, and commercial products and services on a global scale. The company operates through three primary segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides an extensive range of products, including mass spectrometers, flow cytometry solutions, genomics instruments, lab automation systems, centrifugation devices, particle counting and characterization tools, and microscopes. This segment is also engaged in genomics consumables and Gene and Cell Therapy, in addition to offering bioprocess technologies, consumables, and services. Furthermore, it supplies filtration, separation, and purification technologies catering to pharmaceutical and biopharmaceutical companies, as well as food and beverage firms, medical institutions, universities, and various industrial manufacturers. The Diagnostics segment delivers a comprehensive suite of diagnostic solutions, which includes chemistry, immunoassay, microbiology, and automation systems alongside an array of hematology, molecular, acute care, and pathology diagnostics products. This segment also encompasses clinical instruments, reagents, consumables, software, and services that are essential for hospitals, physicians’ offices, reference laboratories, and other critical care environments. Meanwhile, the Environmental & Applied Solutions segment focuses on providing instrumentation, consumables, software, services, and disinfection systems designed to analyze, treat, and manage various types of water across residential, commercial, industrial, and natural resource applications. Moreover, it offers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality management, as well as printing, marking, coding, and traceability applications across consumer, pharmaceutical, and industrial sectors. The company, originally known as Diversified Mortgage Investors, Inc., rebranded as Danaher Corporation in 1984. Established in 1969, the company is headquartered in Washington, D.C. The income before tax ratio is 0.19 reflecting the pre-tax margin. The company reported a substantial revenue of $23,875,000,000.00 reflecting its strong market presence. The EBITDA is $7,276,000,000.00 a key indicator of the company's operational profitability. The company reported an income before tax of $4,646,000,000.00 showcasing its pre-tax profitability. Additionally, the company reported selling, general, and administrative expenses of $7,438,000,000.00 indicating its operational overhead costs. Danaher Corporation’s stock is priced at $197.75 positioning it in the higher-end market. The stock has a high average trading volume of 3,986,522.00 indicating strong liquidity. With a large market capitalization of $151,946,234,400.00 the company is a dominant player. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth.
Investing in Danaher Corporation (DHR) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
Analysts predict Danaher Corporation stock to fluctuate between $171 (low) and $279.90 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-08-20, Danaher Corporation's market cap is $151,946,234,400, based on 716,052,000 outstanding shares.
Compared to Eli Lilly & Co., Danaher Corporation has a Lower Market-Cap, indicating a difference in performance.
Danaher Corporation pays dividends. The current dividend yield is 0.59%, with a payout of $0.32 per share.
To buy Danaher Corporation (DHR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DHR. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Danaher Corporation's last stock split was 141:125 on 2023-10-02.
Revenue: $23,875,000,000 | EPS: $5.33 | Growth: -17.24%.
Visit https://www.danaher.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $333.96 (2021-09-10) | All-time low: $171 (2025-04-09).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Danaher (DHR) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, DHR broke through the 200-day moving average, which suggests a long-term bullish trend.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR). If you currently own shares of Danaher stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=17717 for more information. You may also contact Phillip Kim of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected]. Why Rosen Law: We e.
zacks.com
Investors with an interest in Medical Services stocks have likely encountered both CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
benzinga.com
DHR reverses early down move after Alert
zacks.com
Explore how Danaher's (DHR) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
youtube.com
'Mad Money' host Jim Cramer talks how to play Danaher after earnings.
seekingalpha.com
While the worst seem to be behind them, the business isn't quite humming enough to get investors excited yet. Revenue growth guidance for 2025 remains unchanged at 3%. But they did raise full year adjusted diluted net EPS guidance to a range of $7.70 to $7.80 vs previous range of $7.60 to $7.75. Compared to the past few years, Danaher's multiples have noticeably come down. However, it is hard for a stock to go up if revenue growth hovers around LSD level.
zacks.com
Investors interested in Medical Services stocks are likely familiar with CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
seekingalpha.com
Danaher Corporation is returning to growth, led by strong bioprocessing demand and resilient diagnostics, with Life Sciences expected to recover in late 2025. Margins may face short-term pressure, but a $150M cost-reduction plan and easing China headwinds should drive margin expansion from FY26 onward. The stock trades at a meaningful discount to historical valuation, offering compelling upside as earnings growth is set to reaccelerate post-FY25.
See all news